Oramed Pharmaceuticals (ORMP) EBIT Margin (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly EBIT Margin came in at 225.0% in Q1 2025, up 60.0% on a QoQ basis from 562.46% in Q2 2023.

Oramed Pharmaceuticals (ORMP) EBIT Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 8 years of EBIT Margin data on file, last reported at 225.0% in Q1 2025.

Quarterly EBIT Margin changed N/A year-over-year to 225.0% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 754.4% (changed N/A YoY) and the FY2025 annual result came in at 754.4%, changed N/A from the prior year.
EBIT Margin climbed to 225.0% in Q1 2025, from 562.46% in the prior quarter.
In the past five years, EBIT Margin ranged from a high of 225.0% in Q1 2025 to a low of 1693.92% in Q2 2022.
A 4-year average of 1051.65% and a median of 1048.44% in 2021 frame the typical range for EBIT Margin.
The widest YoY moves for EBIT Margin: up 113145 bps in 2023, down 90751 bps in 2023.
Tracing ORMP's EBIT Margin over 4 years: stood at 896.15% in 2021, then slumped by 52 bps to 1363.5% in 2022, then soared by 59 bps to 562.46% in 2023, then soared by 60 bps to 225.0% in 2025.
The last three EBIT Margin figures came in at 225.0% (Q1 2025), 562.46% (Q2 2023), and 781.98% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Oramed Pharmaceuticals	196.17 Mn	196.17 Mn	-	-

Download Data